RAD Approval for Phase 1 Therapeutic Trial of RAD 402
Filed with ASX · · 2 pages · English
Radiopharm Theranostics Limited on 6ix
In the deck
Story so far
Earlier from Radiopharm Theranostics
- Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases
- RAD Announces 50% Enrollment in Phase 2b Trial of RAD101
- Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204
- RAD starts enrollment of 3rd Cohort of Phase 1 177Lu-RAD204
- Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
Later from Radiopharm Theranostics
- Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer
- Amendment to Annual Report by Foreign Issuer (Form 20-F/A)
- RAD101 interim Phase 2b data - 92% achieve primary endpoint
- Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
- RAD Increases Ownership in Radiopharm Ventures to 87.5%
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics